Patients who took Favipiravir recovered quicker and showed greater lung improvement compared with patients not given the drug.

The component is thought to block the virus from replicating in the body.


Doses will be investigated in more COVID-19 patients by Hong Kong researchers, who claim they will give their pill 'for free' if studies show it is safe.

However, contradictory clinical trials suggest Favipiravir will not be useful in patients who have more severe illness.

As of yet, there isn't a treatment for the new coronavirus causing a global pandemic. Most people have mild symptoms and can recover at home within a week.

Almost 200,000 have been infected and 7,9000 have died.

Avipiravir is an active ingredient which has shown to be effective against flu strains, yellow fever, foot-and-mouth-disease and some other virus families.

It was given to 80 patients in Shenzen and in Wuhan, where the novel coronavirus first emerged in December 2019.

Favipiravir has been effective, with no obvious side-effects, in helping coronavirus patients recover, Zhang Xinmin, an official at China's Science and Technology Ministry, told reporters at a news conference on Tuesday.

It has a high degree of safety and is clearly effective in treatment,' Mr Xinmin said, according to The Guardian.

Patients who were given the medicine in Shenzhen had negative results for the coronavirus an average of four days after being diagnosed, meaning there was no trace of the virus in their body.

This compared with 11 days for those who were not treated with the drug, according to local media.

X-rays showed improvements in lung condition in nine in ten of the patients who were treated with Favipiravir, compared to six in ten of those without the drug.

It is not clear what the results were in patients in Wuhan.

It's also unknown which branded Favipiravir drug the patients were given.

One of the most known is Avigan, manufactured by a subsidiary of Fujifilm, which is better known for its cameras. The drug was approved for use in Japan in 2014 as a new flu treatment.

Fujifilm Toyama Chemical, the medical arm of Fujifilm – has declined to comment on the clinical trial, The Guardian reports.

An oral medicine using favipiravir, developed by Hong Kong-based Sihuan Pharmaceutical, is also in line to try on COVID-19 patients.

Led by Beijing Chaoyang Hospital, a clinical trial is part of a program by Sihuan and the Institute of Microbiology Epidemiology, a division of the Chinese armed forces.

The study will involve 60 COVID-19 patients who will be given treatment for around 10 days. Larger trials are expected after.

Sihuan executive director Che Fengsheng said: 'After all the efforts and preparations, our group is fully prepared for favipiravir's raw material and preparation production.

'Once approved, favipiravir tablets will be provided for free as a treatment protection for COVID-19 patients during the epidemic, bringing good news to patients.'

Source: https://www.dailymail.co.uk/news/article-8125513/Drug-used-treat-flu-Japan-clearly-effective-Chinese-officials-say.html

Ok o If it is the truth

Long Overdue, Wat nonsense and ingredient coronavirus

Ok

I hope this save the world🙏

geraldboss:
I hope this save the world🙏

really hope so as well

Corona virus will be history very soon

China na una bring corona virus to the world make una find the way to eliminate this Chinese virus we Nigerians they beg you people for 9ja our president no dey hear word

okay

Before posting this kind write up do fact finding.
I guess this is written early in the week because number of infected persons is approaching 300k already while your article have 200k, also number of deaths is +/-12k while your article says 7k.
Hope you learned @OP